Lung Cancer
Web Exclusives | February 22, 2022
The chemistry behind selective KRAS G12C therapies and potential future research avenues were discussed in a recently released journal article.
Web Exclusives | February 22, 2022
In a recent study, researchers identified several factors associated with the development of pneumonitis with therapies targeting non–small-cell lung cancer.
Web Exclusives | February 22, 2022
Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article.
Web Exclusives | February 22, 2022
Although generally mild adverse events are associated with the use of immune checkpoint inhibitors for non–small-cell lung cancer, occasionally serious complications may result.
Web Exclusives | January 25, 2022
A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs.
Web Exclusives | January 25, 2022
Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors.
Web Exclusives | January 25, 2022
A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin.
Web Exclusives | January 25, 2022
A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Patients who take immune checkpoint inhibitors experience a small number of severe side effects, although the majority of them recover with treatment.
2021 Year in Review: Non–Small-Cell Lung Cancer | December 29, 2021
Sotorasib and adagrasib show promising clinical activity against KRASG12C mutations in patients with NSCLC, giving new hope for patients with the previously regarded “undruggable” disease.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512